Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 05/24/22
End: 12/15/23
Due: 12/15/24
Phase: N/A
Priority: Normal
Start: 10/05/23
End: 02/20/25
Due: 02/20/26
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Phase 2 Study of VGT-309 in Lung Cancer | NCT05400226 | Vergent Bioscience, Inc. | user2@example.com | None | 2022-05-24 | 2023-12-15 | 2024-12-15 | - | - | 2025-07-14 |
| Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung. | NCT06145048 | Vergent Bioscience, Inc. | user2@example.com | None | 2023-10-05 | 2025-02-20 | 2026-02-20 | - | - | 2025-07-14 |